About the Company
We do not have any company description for Century Therapeutics, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Century Therapeutics, Inc.
Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today ...
Century Therapeutics Reports Q2 2025 Financials and Updates
Century Therapeutics, Inc. ( (IPSC) ) has released its Q2 earnings. Here is a breakdown of the information Century Therapeutics, Inc. presented to its investors.Elevate Your Investing Strategy: Take ...
Century Therapeutics, Inc. (IPSC) Q1 Earnings and Revenues Top Estimates
Century Therapeutics (IPSC) delivered earnings and revenue surprises of 387.10% and 139.84%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Century Therapeutics, Inc.: Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Patient dosing ongoing in CALiPSO-1 trial; on track to report clinical data for CNTY-101 in patients with B-cell-mediated autoimmune diseases by year-end 2025CNTY-308, a CAR-iT cell therapy functional ...
Century Therapeutics, Inc. (IPSC) Reports Q4 Loss, Misses Revenue ...
Century Therapeutics, Inc., which belongs to the Zacks Medical - Drugs industry, posted revenues of $0.52 million for the quarter ended December 2022, missing the Zacks Consensus Estimate by 81.41%.
Century Therapeutics, Inc. Demonstrates Strong Financial Management ...
Century Therapeutics, Inc. Demonstrates Strong Financial Management with No Senior Securities Defaults November 07, 2024 — 01:02 am EST Written by TipRanks Auto-Generated Newsdesk for TipRanks -> ...
Century Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA, as ...
PHILADELPHIA, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (IPSC) (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell ...
Century Therapeutics, Inc. Demonstrates Strong Financial Management ...
Century Therapeutics, Inc. does not currently face any risks related to defaults upon senior securities, as indicated by the absence of such defaults.
Century Therapeutics, Inc. (IPSC) Reports Q3 Loss, Tops Revenue ... - AOL
Century Therapeutics, Inc. , which belongs to the Zacks Medical - Drugs industry, posted revenues of $2.22 million for the quarter ended September 2022, surpassing the Zacks Consensus Estimate by ...
Similar Companies
Loading the latest forecasts...